DYN
Dyne Therapeutics, Inc.
Price Chart
Latest Quote
$25.43
+0.36 (+1.44%)
Current Price
| Previous Close | $25.07 |
| Open | $24.92 |
| Day High | $25.65 |
| Day Low | $24.58 |
| Volume | 2,691,616 |
Stock Information
| Shares Outstanding | 186.75M |
| Total Debt | $233.35M |
| Cash Equivalents | $898.48M |
| Net Income | $-519.40M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $4.75B |
| EPS (TTM) | $-3.26 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $4.08B |
| Income | $-519.40M |
| Book/sh | $4.24 |
| Cash/sh | $4.81 |
| Employees | 289 |
Financial Ratios
| Quick Ratio | 11.52 |
| Current Ratio | 12.02 |
| Debt/Eq | 33.23 |
Returns & Margins
| ROA | -38.96% |
| ROE | -81.57% |
Ownership
| Insider Ownership | 0.24% |
| Institutional Ownership | 103.69% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -7.61 |
| P/B | 6.00 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $39.40 |
Technical Indicators
| SMA20 | $26.09 |
| SMA50 | $24.31 |
| SMA200 | $19.78 |
| RSI | 39.15 |
| ATR | 0.9163 |
| Shares Float | 186.27M |
| Short Float | 14.70% |
| Short Ratio | 8.42 |
| Volatility | 1.08 |
| Rel Volume | 1.53 |
Performance History
| Week | -2.57% |
| Month | -1.17% |
| Quarter | +31.56% |
| 6 Months | +62.80% |
| YTD | +37.46% |
| Year | +86.44% |
| 3 Years | +119.04% |
| 5 Years | +58.05% |
| 10 Years | +6.40% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-08-31 | $25.43 | 2,769,300 |
| 2026-08-27 | $26.09 | 1,018,700 |
| 2026-08-26 | $26.36 | 1,527,800 |
| 2026-08-25 | $26.34 | 1,459,200 |
| 2026-08-24 | $25.99 | 1,370,100 |
| 2026-08-21 | $26.10 | 1,181,800 |
| 2026-08-20 | $25.98 | 1,484,300 |
| 2026-08-19 | $26.78 | 1,952,000 |
| 2026-08-18 | $26.00 | 1,900,700 |
| 2026-08-17 | $26.15 | 1,317,600 |
| 2026-08-14 | $25.70 | 1,684,500 |
| 2026-08-13 | $25.96 | 1,901,600 |
| 2026-08-12 | $26.17 | 1,781,400 |
| 2026-08-11 | $26.71 | 1,398,900 |
| 2026-08-10 | $26.50 | 3,022,600 |
| 2026-08-07 | $26.25 | 1,991,000 |
| 2026-08-06 | $25.88 | 1,330,600 |
| 2026-08-05 | $26.17 | 2,152,600 |
| 2026-08-04 | $25.97 | 2,774,200 |
| 2026-08-03 | $25.24 | 2,131,900 |
About Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
đ° Latest News
Dyne Therapeutics (DYN) Prices Upsized Share Offering, Is The Valuation Still Compelling?
Simply Wall St. âĸ 2026-07-23T11:08:48Z
SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat?
Zacks âĸ 2026-07-22T13:25:00Z
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Ahead of Major Tech Earnings
MT Newswires âĸ 2026-07-22T13:01:02ZDyne Therapeutics shares slide after pricing $375 million public offering (NASDAQ:DYN)
InvestorsHub âĸ 2026-07-22T12:29:28Z
Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock
Stocktwits âĸ 2026-07-22T00:06:24Z
SRPT Stock Drops 4% As Citi Flags Potentially Stronger Rival In Duchenne Space
Stocktwits âĸ 2026-07-21T20:04:11Z
DYN Stock Rises 19.2% in 3 Months: What's Driving the Rally?
Zacks âĸ 2026-07-21T14:20:00Z
Sarepta Skids After A Rival Clears A Key Hurdle In The Duchenne Space
Investor's Business Daily âĸ 2026-07-20T20:28:10Z
Dyne Therapeutics (DYN) Inspires Confidence With Its Force Platform
Insider Monkey âĸ 2026-07-15T14:01:50Z
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?
Motley Fool âĸ 2026-07-04T13:41:09Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $6,192,000 | $0 | $0 | - |
| Total Expenses | $468,184,000 | $343,886,000 | $242,162,000 | $170,962,000 |
| Other Income Expense | $-1,697,000 | $-454,000 | $-1,416,000 | $-54,000 |
| Other Non Operating Income Expenses | $-1,697,000 | $-454,000 | $-1,416,000 | $-54,000 |
| Net Non Operating Interest Income Expense | $23,667,000 | $26,922,000 | $7,641,000 | $2,917,000 |
| Interest Expense Non Operating | $6,192,000 | $0 | $0 | - |
| Operating Expense | $468,184,000 | $343,886,000 | $242,162,000 | $170,962,000 |
| General And Administrative Expense | $69,851,000 | $62,480,000 | $31,400,000 | $28,202,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-446,214,000 | $-317,418,000 | $-235,937,000 | $-168,099,000 |
| Net Interest Income | $23,667,000 | $26,922,000 | $7,641,000 | $2,917,000 |
| Interest Income | $29,859,000 | $26,922,000 | $7,641,000 | $2,917,000 |
| Normalized Income | $-446,214,000 | $-317,418,000 | $-235,937,000 | $-168,099,000 |
| Net Income From Continuing And Discontinued Operation | $-446,214,000 | $-317,418,000 | $-235,937,000 | $-168,099,000 |
| Total Operating Income As Reported | $-468,184,000 | $-343,886,000 | $-242,162,000 | $-170,962,000 |
| Net Income Common Stockholders | $-446,214,000 | $-317,418,000 | $-235,937,000 | $-168,099,000 |
| Net Income | $-446,214,000 | $-317,418,000 | $-235,937,000 | $-168,099,000 |
| Net Income Including Noncontrolling Interests | $-446,214,000 | $-317,418,000 | $-235,937,000 | $-168,099,000 |
| Net Income Continuous Operations | $-446,214,000 | $-317,418,000 | $-235,937,000 | $-168,099,000 |
| Pretax Income | $-446,214,000 | $-317,418,000 | $-235,937,000 | $-168,099,000 |
| Interest Income Non Operating | $29,859,000 | $26,922,000 | $7,641,000 | $2,917,000 |
| Operating Income | $-468,184,000 | $-343,886,000 | $-242,162,000 | $-170,962,000 |
| Per Share | ||||
| Diluted EPS | $-3.47 | $-3.37 | $-3.95 | $-3.23 |
| Basic EPS | $-3.47 | $-3.37 | $-3.95 | $-3.23 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-437,973,000 | $-315,745,000 | $-234,264,000 | $-169,279,000 |
| Reconciled Depreciation | $2,049,000 | $1,673,000 | $1,673,000 | $1,683,000 |
| EBITDA (Bullshit earnings) | $-437,973,000 | $-315,745,000 | $-234,264,000 | $-169,279,000 |
| EBIT | $-440,022,000 | $-317,418,000 | $-235,937,000 | $-170,962,000 |
| Diluted Average Shares | $128,442,723 | $94,143,565 | $59,683,851 | $51,976,343 |
| Basic Average Shares | $128,442,723 | $94,143,565 | $59,683,851 | $51,976,343 |
| Diluted NI Availto Com Stockholders | $-446,214,000 | $-317,418,000 | $-235,937,000 | $-168,099,000 |
| Research And Development | $398,333,000 | $281,406,000 | $210,762,000 | $142,760,000 |
| Selling General And Administration | $69,851,000 | $62,480,000 | $31,400,000 | $28,202,000 |
| Other Gand A | $31,329,000 | $22,812,000 | $31,400,000 | $28,202,000 |
| Salaries And Wages | $38,522,000 | $39,668,000 | $18,018,000 | $14,749,000 |
Fetched: 2026-08-31
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $972,129,000 | $629,838,000 | $91,292,000 | $252,364,000 |
| Total Assets | $1,186,958,000 | $691,234,000 | $165,082,000 | $306,325,000 |
| Total Non Current Assets | $60,371,000 | $31,955,000 | $35,707,000 | $40,731,000 |
| Other Non Current Assets | $15,600,000 | $1,942,000 | $2,315,000 | $2,319,000 |
| Current Assets | $1,126,587,000 | $659,279,000 | $129,375,000 | $265,594,000 |
| Other Current Assets | $16,025,000 | $17,011,000 | $6,275,000 | $9,582,000 |
| Cash Cash Equivalents And Short Term Investments | $1,110,562,000 | $642,268,000 | $123,100,000 | $256,012,000 |
| Cash And Cash Equivalents | $893,369,000 | $435,449,000 | $121,626,000 | $172,147,000 |
| Cash Equivalents | - | - | $84,868,000 | $14,044,000 |
| Cash Financial | - | - | $36,758,000 | $158,103,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $169,199,000 | $23,988,000 | $27,415,000 | $30,483,000 |
| Long Term Debt And Capital Lease Obligation | $164,204,000 | $19,138,000 | $22,695,000 | $25,873,000 |
| Long Term Debt | $148,921,000 | - | - | - |
| Current Debt And Capital Lease Obligation | $4,995,000 | $4,850,000 | $4,720,000 | $4,610,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $214,829,000 | $61,396,000 | $73,790,000 | $53,961,000 |
| Total Non Current Liabilities Net Minority Interest | $164,204,000 | $19,138,000 | $22,695,000 | $25,873,000 |
| Current Liabilities | $50,625,000 | $42,258,000 | $51,095,000 | $28,088,000 |
| Payables And Accrued Expenses | $45,630,000 | $37,408,000 | $46,375,000 | $23,478,000 |
| Interest Payable | $1,189,000 | $0 | - | - |
| Payables | $8,082,000 | $6,562,000 | $22,936,000 | $5,259,000 |
| Accounts Payable | $8,082,000 | $6,562,000 | $22,936,000 | $5,259,000 |
| Equity | ||||
| Common Stock Equity | $972,129,000 | $629,838,000 | $91,292,000 | $252,364,000 |
| Total Equity Gross Minority Interest | $972,129,000 | $629,838,000 | $91,292,000 | $252,364,000 |
| Stockholders Equity | $972,129,000 | $629,838,000 | $91,292,000 | $252,364,000 |
| Gains Losses Not Affecting Retained Earnings | $475,000 | $6,000 | $0 | $-571,000 |
| Other Equity Adjustments | $475,000 | $6,000 | - | $-571,000 |
| Retained Earnings | $-1,396,142,000 | $-949,928,000 | $-632,510,000 | $-396,573,000 |
| Other | ||||
| Ordinary Shares Number | $164,950,540 | $102,318,629 | $61,468,743 | $55,636,505 |
| Share Issued | $164,950,540 | $102,318,629 | $61,468,743 | $55,636,505 |
| Tangible Book Value | $972,129,000 | $629,838,000 | $91,292,000 | $252,364,000 |
| Invested Capital | $1,121,050,000 | $629,838,000 | $91,292,000 | $252,364,000 |
| Working Capital | $1,075,962,000 | $617,021,000 | $78,280,000 | $237,506,000 |
| Capital Lease Obligations | $20,278,000 | $23,988,000 | $27,415,000 | $30,483,000 |
| Total Capitalization | $1,121,050,000 | $629,838,000 | $91,292,000 | $252,364,000 |
| Additional Paid In Capital | $2,367,780,000 | $1,579,750,000 | $723,796,000 | $649,502,000 |
| Capital Stock | $16,000 | $10,000 | $6,000 | $6,000 |
| Common Stock | $16,000 | $10,000 | $6,000 | $6,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $15,283,000 | $19,138,000 | $22,695,000 | $25,873,000 |
| Current Capital Lease Obligation | $4,995,000 | $4,850,000 | $4,720,000 | $4,610,000 |
| Current Accrued Expenses | $37,548,000 | $30,846,000 | $23,439,000 | $18,219,000 |
| Net PPE | $44,771,000 | $30,013,000 | $33,392,000 | $38,412,000 |
| Accumulated Depreciation | $-8,721,000 | $-6,773,000 | $-5,288,000 | $-3,629,000 |
| Gross PPE | $53,492,000 | $36,786,000 | $38,680,000 | $42,041,000 |
| Construction In Progress | $19,305,000 | $619,000 | $431,000 | $906,000 |
| Other Properties | $31,639,000 | $33,812,000 | $36,158,000 | $39,237,000 |
| Machinery Furniture Equipment | $2,548,000 | $2,355,000 | $2,091,000 | $1,898,000 |
| Other Short Term Investments | $217,193,000 | $206,819,000 | $1,474,000 | $83,865,000 |
| Treasury Shares Number | - | - | - | - |
| Leases | - | - | - | - |
| Properties | - | - | - | - |
Fetched: 2026-08-31
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-423,917,000 | $-294,745,000 | $-188,887,000 | $-156,712,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-403,207,000 | $-292,369,000 | $-188,158,000 | $-153,645,000 |
| Cash Flow From Continuing Operating Activities | $-403,207,000 | $-292,369,000 | $-188,158,000 | $-153,645,000 |
| Operating Gains Losses | $65,000 | $37,000 | $141,000 | $34,000 |
| Investing Activities | ||||
| Capital Expenditure | $-20,710,000 | $-2,376,000 | $-729,000 | $-3,067,000 |
| Investing Cash Flow | $-28,751,000 | $-204,076,000 | $83,311,000 | $87,202,000 |
| Cash Flow From Continuing Investing Activities | $-28,751,000 | $-204,076,000 | $83,311,000 | $87,202,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $734,610,000 | $773,051,000 | $52,369,000 | $36,861,000 |
| Financing Cash Flow | $890,307,000 | $809,895,000 | $54,322,000 | $37,390,000 |
| Cash Flow From Continuing Financing Activities | $890,307,000 | $809,895,000 | $54,322,000 | $37,390,000 |
| Net Other Financing Charges | $-558,000 | - | - | - |
| Net Common Stock Issuance | $734,610,000 | $773,051,000 | $52,369,000 | $36,861,000 |
| Common Stock Issuance | $734,610,000 | $773,051,000 | $52,369,000 | $36,861,000 |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| Issuance Of Debt | $148,256,000 | $0 | $0 | - |
| Interest Paid Supplemental Data | $4,339,000 | $0 | $0 | - |
| End Cash Position | $895,740,000 | $437,391,000 | $123,941,000 | $174,466,000 |
| Beginning Cash Position | $437,391,000 | $123,941,000 | $174,466,000 | $203,519,000 |
| Changes In Cash | $458,349,000 | $313,450,000 | $-50,525,000 | $-29,053,000 |
| Proceeds From Stock Option Exercised | $7,999,000 | $36,844,000 | $1,953,000 | $529,000 |
| Net Issuance Payments Of Debt | $148,256,000 | $0 | $0 | - |
| Net Long Term Debt Issuance | $148,256,000 | $0 | $0 | - |
| Long Term Debt Issuance | $148,256,000 | $0 | $0 | - |
| Net Investment Purchase And Sale | $-8,041,000 | $-201,700,000 | $84,040,000 | $90,269,000 |
| Sale Of Investment | $172,493,000 | $115,743,000 | $128,302,000 | $211,445,000 |
| Purchase Of Investment | $-180,534,000 | $-317,443,000 | $-44,262,000 | $-121,176,000 |
| Net PPE Purchase And Sale | $-20,710,000 | $-2,376,000 | $-729,000 | $-3,067,000 |
| Purchase Of PPE | $-20,710,000 | $-2,376,000 | $-729,000 | $-3,067,000 |
| Change In Working Capital | $-3,404,000 | $-19,491,000 | $26,307,000 | $-5,379,000 |
| Change In Other Current Assets | $-12,641,000 | $0 | $0 | $0 |
| Change In Payables And Accrued Expense | $8,251,000 | $-8,955,000 | $22,970,000 | $-1,235,000 |
| Change In Payable | $8,251,000 | $-8,955,000 | $22,970,000 | $-1,235,000 |
| Change In Account Payable | $8,251,000 | $-8,955,000 | $22,970,000 | $-1,235,000 |
| Change In Prepaid Assets | $986,000 | $-10,536,000 | $3,337,000 | $-4,144,000 |
| Other Non Cash Items | $281,000 | $570,000 | $788,000 | $1,662,000 |
| Stock Based Compensation | $45,851,000 | $45,864,000 | $19,972,000 | $15,178,000 |
| Amortization Of Securities | $-1,835,000 | $-3,604,000 | $-1,102,000 | $1,276,000 |
| Depreciation Amortization Depletion | $2,049,000 | $1,673,000 | $1,673,000 | $1,683,000 |
| Depreciation And Amortization | $2,049,000 | $1,673,000 | $1,673,000 | $1,683,000 |
| Gain Loss On Investment Securities | $-30,000 | $-35,000 | $23,000 | $34,000 |
| Gain Loss On Sale Of PPE | $95,000 | $72,000 | $118,000 | $0 |
| Net Income From Continuing Operations | $-446,214,000 | $-317,418,000 | $-235,937,000 | $-168,099,000 |
| Repayment Of Debt | - | - | - | - |
| Long Term Debt Payments | - | - | - | - |
Fetched: 2026-08-31